DK2582721T3 - USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION - Google Patents

USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION Download PDF

Info

Publication number
DK2582721T3
DK2582721T3 DK11796555.8T DK11796555T DK2582721T3 DK 2582721 T3 DK2582721 T3 DK 2582721T3 DK 11796555 T DK11796555 T DK 11796555T DK 2582721 T3 DK2582721 T3 DK 2582721T3
Authority
DK
Denmark
Prior art keywords
ser
thr
gly
val
leu
Prior art date
Application number
DK11796555.8T
Other languages
Danish (da)
English (en)
Inventor
Lawrence M Kauvar
Stote Ellsworth
William Usinger
Krista Maureen Mccutcheon
Minha Park
Original Assignee
Trellis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Llc filed Critical Trellis Bioscience Llc
Application granted granted Critical
Publication of DK2582721T3 publication Critical patent/DK2582721T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK11796555.8T 2010-06-17 2011-06-17 USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION DK2582721T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35597810P 2010-06-17 2010-06-17
US201161443103P 2011-02-15 2011-02-15
US201161445455P 2011-02-22 2011-02-22
PCT/US2011/040982 WO2011160083A1 (en) 2010-06-17 2011-06-17 Antibodies useful in passive influenza immuization

Publications (1)

Publication Number Publication Date
DK2582721T3 true DK2582721T3 (en) 2018-10-01

Family

ID=45348575

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11796555.8T DK2582721T3 (en) 2010-06-17 2011-06-17 USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION

Country Status (12)

Country Link
US (1) US10676520B2 (enExample)
EP (1) EP2582721B1 (enExample)
JP (1) JP6050747B2 (enExample)
KR (1) KR101849738B1 (enExample)
CN (2) CN103209994B (enExample)
AU (2) AU2011268072C1 (enExample)
BR (1) BR112012032185A2 (enExample)
CA (1) CA2839421C (enExample)
DK (1) DK2582721T3 (enExample)
ES (1) ES2687706T3 (enExample)
RU (1) RU2635999C2 (enExample)
WO (1) WO2011160083A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367743B (es) 2011-12-05 2019-09-04 Trellis Bioscience Llc Anticuerpos utiles para la inmunizacion pasiva de influenza.
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
BR112015010817A8 (pt) 2012-11-13 2018-01-23 Genentech Inc anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
IL241552B2 (en) 2013-03-14 2023-09-01 Contrafect Corp Preparation and methods based on neutralizing antibodies administered intranasally for increased therapeutic efficacy
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
AU2015214146B2 (en) 2014-02-04 2020-09-17 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
EA201691481A1 (ru) * 2014-03-20 2017-02-28 Инфларкс Гмбх ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
CA3028035A1 (en) * 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
EP3731862A1 (en) * 2017-12-29 2020-11-04 Development Center for Biotechnology A universal vaccine against influenza
SG11202006379UA (en) 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235708B1 (en) 1998-11-20 2001-05-22 Zymogenetics, Inc Testis-specific cystatin-like protein cystatin T
US20020006656A1 (en) 1999-12-23 2002-01-17 Holloway James L. Zcys5: a member of the cystatin superfamily
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
EP1603590A4 (en) 2003-03-07 2008-08-27 Merck & Co Inc INFLUENZA VIRUS VACCINE
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
WO2005007697A1 (ja) * 2003-07-23 2005-01-27 Fujirebio Inc. 抗インフルエンザａ型ウイルスモノクローナル抗体及び該抗体を用いる免疫測定器具
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
JP2009537147A (ja) * 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
CA2663388C (en) * 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP3524619A1 (en) * 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
CA2719201A1 (en) * 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc. Neutralizing molecules to viral antigens
CA2731686C (en) * 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
AR073072A1 (es) 2008-08-19 2010-10-13 Regeneron Pharma Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
AU2008365616A1 (en) * 2008-12-24 2011-08-11 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
HRP20170490T1 (hr) 2010-03-26 2017-06-02 Pomona Ricerca S.R.L. Imunoglobulini pune dužine igg izotipa sposobni za prepoznavanje heterosubtipnog epitopa neutralizacije na području stabljike hemaglutinina i njihova uporaba kao lijek protiv gripe
EP2603237A4 (en) * 2010-08-12 2014-05-21 Theraclone Sciences Inc ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
WO2012045001A2 (en) * 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor

Also Published As

Publication number Publication date
AU2011268072A2 (en) 2013-02-28
CA2839421A1 (en) 2011-12-22
EP2582721A4 (en) 2013-11-20
EP2582721A1 (en) 2013-04-24
WO2011160083A1 (en) 2011-12-22
ES2687706T3 (es) 2018-10-26
JP2013531993A (ja) 2013-08-15
EP2582721B1 (en) 2018-08-22
AU2017203924B2 (en) 2019-08-08
CA2839421C (en) 2019-12-03
CN106397584A (zh) 2017-02-15
RU2013102073A (ru) 2014-07-27
CN103209994A (zh) 2013-07-17
AU2017203924A1 (en) 2017-07-06
KR101849738B1 (ko) 2018-04-17
RU2635999C2 (ru) 2017-11-17
US20120020971A1 (en) 2012-01-26
US10676520B2 (en) 2020-06-09
CN103209994B (zh) 2016-10-12
AU2011268072A1 (en) 2013-01-31
JP6050747B2 (ja) 2016-12-21
AU2011268072C1 (en) 2017-10-19
KR20130137584A (ko) 2013-12-17
BR112012032185A2 (pt) 2016-10-11
AU2011268072B2 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
KR101849738B1 (ko) 수동 인플루엔자 면역에 유용한 항체
AU2012347878B2 (en) Antibodies useful in passive influenza immunization
KR102535195B1 (ko) 항-코로나바이러스 항체 및 사용 방법
AU2020203853C1 (en) Human immunodeficiency virus (HIV)-neutralizing antibodies
AU2021227687B2 (en) Antibodies against SARS-CoV-2 and methods of using the same
KR102602417B1 (ko) G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법
CN108640989B (zh) 可结合并中和b型流感病毒的人类结合分子及其用途
EP3689909A1 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
KR20230002261A (ko) 항-sars-cov-2 중화 항체 및 이의 사용 방법
CN115768790A (zh) 针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的人单克隆抗体
KR20220038415A (ko) 엔테로바이러스 d68에 대한 인간 모노클로날 항체
CN116194476A (zh) 针对sars-cov-2的抗体和其使用方法
TW200925279A (en) Methods for recombinant manufacturing of anti-RSV antibodies
CN101679513A (zh) 用于治疗呼吸道合胞病毒感染的重组抗体
CN114685652B (zh) 针对SARS-CoV-2和SARS-CoV的全人广谱交叉中和抗体及其应用
KR20140012098A (ko) 인플루엔자의 치료 및 진단을 위한 조성물 및 방법
KR101900435B1 (ko) 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체
TW202300526A (zh) 針對ｇｄｆ－１５的抗體
AU2025201226A1 (en) Monoclonal antibodies and cocktails for treatment of Ebola infections
KR20230042598A (ko) SARS-CoV-2 중화 항체 또는 그 단편
CN113135994B (zh) 一种激活型抗ox40抗体、生产方法及应用
KR20220098003A (ko) 한타바이러스에 대한 인간 모노클로날 항체 및 이의 사용 방법
CN114685653B (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
CN102238963A (zh) 完全人源性流感m2特异性抗体
KR20210046725A (ko) 신규 암 면역요법 항체 조성물